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reported approximately 20% impairment in productivity due to
psoriasis. Twenty-six percent of the patients indicated psoriasis
was the reason for altering their job type, description, or work
responsibilities. Thirty-four percent of patients believed that
their condition affected their choice of career or ability to ﬁnd a
job. Assuming patients were not paid during their absenteeism,
absence from work resulted in lost mean patient wages of
CDN$2580.97 per person per year. With an estimated 330,000
Canadians suffering from moderate to severe psoriasis, total lost
wages due to moderate to severe psoriasis may cost up to
approximately CDN$852 million for all moderate to severe pso-
riasis patients in Canada. CONCLUSION: The results of this
study indicate that moderate to severe psoriasis may have a
substantial impact on the work productivity of patients with this
disease. Further studies on lost productivity as well as societal
impact of moderate to severe psoriasis are needed.
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OBJECTIVE: To examine the effect of ustekinumab on work
productivity and the number of workdays missed due to pso-
riasis. METHODS: A total of 1995 patients were enrolled in the
PHOENIX I and II trials. Patients were randomized 1:1:1 to
one of three groups:placebo,ustekinumab 45mg,or ustekinumab
90mg.In the ustekinumab groups, patients received treatment at
weeks 0, 4, and every 12 weeks thereafter. Patients randomized
to placebo at baseline crossed-over to receive either 45 mg or
90 mg of ustekinumab at weeks 12, 16, and every 12 weeks
thereafter.Productivity was assessed using a 10cm Visual Analog
Scale (VAS), and change in productivity was recorded in cm
units. Productivity and number of workdays missed due to pso-
riasis in the last 4 weeks was evaluated at weeks 0 and 12 in
both trials. RESULTS: Mean and median baseline productivity
scores and number of workdays missed due to psoriasis were
similar between treatment groups at baseline. At week 12, the
ustekinumab 45 mg and 90 mg groups had signiﬁcantly greater
improvements(p < 0.001 for both comparisons)from baseline in
productivity scores than the placebo group.The mean (median)
change in productivity from baseline score at week 12 was –2.2
(-1.1) for the 45 mg group and –2.4 (-1.4) for the 90 mg
group, compared with 0.0(0.0) for the placebo group. The
mean(median)change from baseline to week 12 in the number
of workdays missed due to psoriasis in the last 4 weeks was 0.0
(0.0) in the placebo group, -0.2 (0.0) in the 45 mg group
(p < 0.002), and -0.3 (0.0) in the 90 mg group (p < 0.002).This
could translate to an annualized average reduction of missed
workdays due to psoriasis of 2.6 days for the 45 mg group and
3.9 days for the 90 mg group. CONCLUSION: Ustekinumab
45 mg and 90 mg resulted in signiﬁcantly improved productivity
compared with placebo in moderate-to-severe psoriasis patients,
as measured by the productivity VAS and workdays missed due
to psoriasis.
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OBJECTIVE: The loss of driving privileges in glaucoma patients
has a signiﬁcant impact on personal, social, and economic well-
being. As a result, glaucoma patients are believed to highly value
any intervention or pharmaceutical agent that can either preserve
or extend visual acuity. The objective of this study was to assess
the willingness to pay to maintain driving privileges in patients
with glaucoma. METHODS: A mailed survey assessing glau-
coma severity, current driving status and willingness to pay for
additional years of driving privileges was sent to a random
sample of 5,000 individuals. A contingent valuation scenario was
posed to individuals as “Your physician tells you that there is a
treatment available for glaucoma that will increase your chances
to see for a longer period of time, and thus maintain your ability
to drive independently. However, the treatment is not covered by
your insurer. If you had to make a decision today, what is the
maximum amount you would be willing to pay for the treatment
in order to maintain driving privileges for one more year?”
RESULTS: A total of 2,009 individuals completed the survey
for a 40% response rate. The majority of the responders were
women (70%) and the mean age of the population was 60.5
(SD = 16.5) years. Over 60% of individuals rated their glaucoma
as mild and 73% of individuals reported that they still drive.
Approximately 43% of responders replied that they would pay
up to $50,000 for one additional year of driving privileges.
CONCLUSION: Driving privileges and personal independence
are highly valued by older individuals. In order to maintain their
driving privileges and personal independence, older individuals
are willing to pay a substantial amount of money to improve
visual acuity.
SENSORY SYSTEMS DISORDERS—Health Care Use &
Policy Studies
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OBJECTIVES: Glaucoma is an optic neuropathy associated with
visual ﬁeld loss. Currently, treatment for glaucoma is focused on
controlling intraocular pressure. First-line treatment typically
involves â-blockers or prostaglandin analogs (PAs). â-blockers
and other intraocular pressure lowering agents (IOPLAs) may be
used as adjunctive therapy to prostaglandins. We quantiﬁed the
use of adjunctive therapy in association with prostaglandins.
METHODS: We conducted a cohort study using pharmacy
dispensing data from The Netherlands using the PHARMO
database. We identiﬁed all patients with a ﬁrst dispensing for
bimatoprost, latanoprost or travoprost between January 2, 1998
and July 1, 2006, and determined the proportions of patients
who received adjunctive therapy in the ﬁrst 12 months of pros-
taglandin use. Use of adjunctive therapy was identiﬁed by at least
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one intermittent dispensing of any IOPLA other than PAs in the
12-month follow-up period from their ﬁrst prostaglandin dis-
pensing. Rates were compared across the three prostaglandin
analogs using chi-square tests. Statistical and descriptive analyses
were performed using SAS 9.1. RESULTS: In total, 9402 patients
were included, aged 70 (SD = 12) years, 56% were female. The
proportions of patients requiring adjunctive therapy were 31%,
42%, and 31% for bimatoprost, latanoprost and travoprost,
respectively. A signiﬁcantly higher proportion of adjunctive
therapy was associated with latanoprost users (bimatoprost vs.
latanoprost: Chi-square = 26.59, p < 0.001; travoprost vs.
latanoprost: Chi-square = 19.82, p < 0.001). Bimatoprost and
travoprost did not differ Chi-square = 0.01, p = 0.94). CON-
CLUSIONS: Approximately 40% of continuous prostaglandin
users required adjunctive therapy in the ﬁrst 12 months. The
latanoprost cohort had the highest rate of adjunctive therapy.
Higher rates of adjunctive therapy use may result in higher
overall patient care costs.
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OBJECTIVE: The objective of this retrospective cohort study is
to understand current treatment patterns of patients with psoria-
sis. METHODS: A total of 56,871patients diagnosed with pso-
riasis (ICD 9: 696.0, 696.1) between index month of June 2005
and March 2007 were selected from the Pharmetrics® database.
Patients with comorbid psoriatic arthritis and/or rheumatoid
arthritis were excluded leaving a sample of 50,075 psoriasis only
patients. Patients included had at least 12-month follow-up as
well as a minimum 2-year history. Treatments included biologic
agents (Amevive, Enbrel, Remicade, Raptiva and Humira), sys-
temic therapies (methotrexate, acitrecin, PUVA, cyclosporine
and other systemic therapies), topicals, and light UVB therapy.
Patients were classiﬁed as “biologic naïve” or “biologic experi-
enced” based on their exposure to the biologic therapies. Patient
treatment dynamics (switching, drop-off therapy, intermittent
and continuous use etc.) were analyzed based on a 12-month
follow up period. RESULTS: A total of 34.6% of the cohort was
newly diagnosed with psoriasis (after the index month of June
2005). About 28% of all patients with psoriasis only were cur-
rently on treatment. Topical therapy only was dominant account-
ing for 72% of all currently treated patients. Biologic use was
observed in <10% of currently treated patients with Enbrel as the
clear market leader accounting for >80% of all biologic usage.
Raptiva was a distant second at 12%. Analysis of treatment
dynamics over a 12-month follow up period revealed a 35%
growth in the biologic exposed population primarily due to the
ﬂow of “biologic naïve” patients to their ﬁrst biologic therapy.
The persistency of Enbrel (67%)and Raptiva (64%) were lower
than that of Remicade (80%). Switching patterns showed limited
sequential use of biologics over a 12-month period. CONCLU-
SION: Use of biologic therapies is currently limited but growing
at a rate of 35%. Enbrel is the market leader and Humira is the
fastest growing biologic in this market.
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OBJECTIVE: To evaluate the impact of psoriasis (PsO) on
health care costs in the ﬁrst year after diagnosis. METHODS: A
retrospective study of the PharMetrics database, compiled from
managed care plans throughout the United States, from January
1, 2000 through December 31, 2006 was conducted. Patients
between the ages of 18 to 80 years, who had a minimum of 12
months of continuous enrollment before and after their index
diagnosis with PsO, were included. The index diagnosis date
was derived from the ﬁrst claim for PsO during the study
period. Health care costs in the years prior to and subsequent to
the diagnosis of PsO were compared. Wilcoxon Signed-Rank
Tests were used to test for signiﬁcant differences between pre-
and post-index periods. The cost of adverse events could not be
identiﬁed separately in this study. RESULTS: The study cohort
included 48,068 patients; 52.3% were females and the mean
age was 46.3 years. The total health care costs increased by
32.73% ($4,834.22 to $6,416.52). The largest cost increase was
for inpatient care (31.8%), followed by pharmacy costs
(25.6%), physician visits (19.7%), out-patient care (11.1%),
other services (8.9%), emergency room (1.5%) and laboratory
services (1.4%). About 75% of the cost increase was for non-
pharmacy related services. All the changes in costs were statis-
tically signiﬁcant (p < 0.001) after the adjustment for inﬂation.
CONCLUSION: This study indicates that following a diagnosis
of PsO, health care costs in the ﬁrst year after such a diagnosis
increases signiﬁcantly. The greatest increase in costs was for
inpatient care, and it is notable that 75% of the increased costs
were for non-pharmacy related services. Additional studies are
needed to further explore the reasons for this large increase in
the cost of treating patients in the ﬁrst year after a diagnosis of
PsO.
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OBJECTIVE: To evaluate the impact of psoriasis (PsO) on
health care utilization and average costs in the ﬁrst year after
diagnosis. METHODS: A retrospective study of the PharMet-
rics database, compiled from managed care plans throughout
the United States, from January 1, 2000 through December 31,
2006 was conducted. Patients between the ages of 18 to 80
years, who had a minimum of 12 months of continuous enroll-
ment before and after their initial diagnosis with PsO, were
included. The index diagnosis date was derived from the ﬁrst
claim for PsO during the study period. RESULTS: The study
cohort included 48,068 patients; 52.3% were female, and the
mean age was 46.3 years. Compared with one year prior to the
diagnosis, the average cost of treating patients in the year after
the diagnosis of PsO was 33% greater (p < 0.0001). Post-
diagnosis utilizations increased by 2.77 physician visits (mean of
8.44 to 11.21), 1.92 prescriptions (mean of 9.56 to 11.48), 0.34
outpatient visit (mean of 1.39 to 1.73), 0.22 laboratory service
(mean of 0.94 to 1.16), 0.02 inpatient stay (mean of 0.13 to
0.15), and 0.02 emergency room visit (mean of 0.18 to 0.20).
Also, the inpatient length of stay increased by 0.34 day (mean
of 1.39 to 1.73). All changes were statically signiﬁcant with
Wilcoxon Signed-Rank Tests (p < 0.001). CONCLUSION: This
study indicates that following a diagnosis of PsO, health care
utilization and average costs in the ﬁrst year after such a diag-
nosis increases signiﬁcantly. While we found that the greatest
increase occurred in the number of physician ofﬁce visits, addi-
tional studies are needed to further explore the reasons for the
large increase (33%) in the cost of treating patients in the ﬁrst
year after a diagnosis of PsO.
Abstracts A299
